What is your strategy to manage the complication of long-term immunosuppression in liver transplant recipients, specifically renal dysfunction and onset of cardiometabolic comorbidities?  

Educating patients early on after their transplant is important as to the medical complications associated with CNI use. With regard to renal dysfunction, trying to minimize CNI use as judiciously and as timely as possible is paramount. Switching to an mTOR inhibitor appears best to do early on afte...

I agree with the recommendations and comments by Dr. @Schiano. The concerns I often have when we co-manage these complications with the PCP are the delay in implementing the valuable use of statins of GLP-1 medications.